… OR triple therapy OR maintenance therapy OR carboplatin and pemetrexed OR cisplatin
AND pemetrexed” AND “advanced non–small-cell lung cancer OR NSCLC”. The search was …

… single-agent pemetrexed versus the combination of carboplatin and pemetrexed in the first-line
… At the time the trial was designed, the combination of pemetrexed with carboplatin was …

… to receive pemetrexed 500 mg/m 2 plus carboplatin area under the curve (AUC) = 5 (Calvert's
formula) on day 1 or gemcitabine 1,000 mg/m 2 on days 1 and 8 plus carboplatin AUC = 5 …

… objectives of this study were to determine the efficacy and tolerability of a pemetrexed-carboplatin
combination as first-line therapy in patients with advanced nonsmall cell lung cancer. …

… that median OS for the docetaxel and carboplatin-pemetrexed groups would be 15 and 18
… the carboplatin-pemetrexed group was 2 or more months shorter than that for the docetaxel …

… pemetrexed-based combination chemotherapy. The obvious candidate to combine with
pemetrexed is … II study comparing pemetrexed with pemetrexed plus carboplatin in patients with …

… ) or etoposide-carboplatin (etoposide 100 mg/m 2 on days 1 through 3; carboplatin AUC 5 on
day … The primary objective of the study was noninferiority of pemetrexed-carboplatin overall …

… In conclusion, combining pemetrexed with either oxaliplatin or carboplatin is safe and effective
for the first-line treatment of locally advanced or metastatic NSCLC. Both regimens seem …

… the pemetrexed/oxaliplatin regimen or pemetrexed/carboplatin… measures, as determined by
the Lung Cancer Symptom Scale. … The cycles delivered were 382 (pemetrexed/carboplatin = …

… compared survival without toxicity in patients with advanced, nonsquamous non-small
cell lung cancer who were treated with first-line pemetrexed/carboplatin or docetaxel/carboplatin. …